Novel drug delivery systems | | | |
Ang-(1–7) eluting stent | Control the release of Ang-(1–7) from the polymer-coated device | Reduces restenosis and improves endothelial cell function | Tijsma et al. (2007) |
βCD/Ang-(1–7) complex | Feasible oral formulation for long-term oral administration of heptapeptide | Modulation of MI proteome dysregulation in an animal model of MI | Lula et al. (2007); Marques et al. (2012); Gómez-Mendoza et al. (2019) |
| | Modulation of diabetes in animal model; modulation of pulmonary emphysema in animal model | Santos et al. (2014); Bastos et al. (2020) |
HPβCD/Ang-(1–7) complex | The inhaled formulation is achieved by incorporation of Ang-(1–7) in HPβCD | Lung protective effect in chronic asthma | (Magalhães et al., 2018) |
PCLf-Ang-(1–7) | Highly porous three-dimensional biodegradable scaffold from BCPg, PCL, and Ang-(1–7) was fabricated | Improvement of degenerative diseases and damaged bone tissue | Macedo et al. (2012) |
Liposomal Ang-(1–7) | Potential of liposomes as a tool for the sustained release of the short half-life Ang-(1–7) was studied | Modulation of circadian rhythm, MAP, and heart rate | Silva-Barcellos et al. (2001) |
Ang-(1–7)/PAMAM-OH | Neutral dendrimers as therapeutic peptide carriers were fabricated | Antiatrophic effect in disuse skeletal muscle tissue in mice | Márquez-Miranda et al. (2017) |
Ang-(1–7) conjugate | Sustained release of the peptide; improved PKh and prolonged biologic half-life | Increasing the RAS protective arm components in an animal model of arthritis | Habashi et al. (2020) |
Structurally modified homologs | | | |
Glycosylated Ang-(1–7) | Improved PK and half-life | Modulation of VCID | Hay et al. (2019) |
Lanthionine-stabilized Ang-(1–7) [cAng-(1–7)] | Improved PK and half-life | Modulation of diabetes in animal model | Kluskens et al. (2009); de Vries et al. (2010); Kuipers et al. (2019) |
| | Improving type 2 diabetic nephropathy | Cassis et al. (2019) |
Acetylation and amination of Ang-(1–7) | Increased peptide stability; improved PK and half-life | Antiproliferative and anti-invasive properties in lung cancer cell line and mice model | Ma et al. (2018) |
Cyclized Ang-(1–7) | Increased peptide stability; improved PK and half-life | Antiproliferative property in breast cancer and fibrosarcoma cells | Wester et al., (2017) |
NorLeu3-Ang-(1–7) | The topical administration | Treating diabetic foot ulcers (in phase III clinical trial) faster than current approved medication | Rodgers et al. (2005, 2011, 2015); Balingit et al. (2012) |
Bio expressing Ang-(1–7) | | | |
L. paracasei modified to express Ang-(1–7) | Subcutaneous delivery of Ang-(1–7) increased circulating Ang-(1–7) and reduced angiotensin II, but most gut-brain parameters were unchanged in response | Anti-inflammatory effect in animal model | Buford et al. (2020); Carter et al. (2020) |
Bioencapsulated plant cells expressing CTB-Ang-(1–7) | Increased shelf-life; improved PK and half-life | Decreasing retinal inflammation in mouse model, inhibiting both progression and commencement of pulmonary hypertension | Shenoy et al. (2014); Lahm et al. (2018); Shil et al. (2014); Daniell et al. (2019) |